Molineaux CJ - Search Results

1

The amino terminus of the human C5a receptor is required for high affinity C5a binding and for receptor activation by C5a but not C5a analogs.

DeMartino JA, Van Riper G, Siciliano SJ, Molineaux CJ, Konteatis ZD, Rosen H, Springer MS. DeMartino JA, et al. Among authors: molineaux cj. J Biol Chem. 1994 May 20;269(20):14446-50. J Biol Chem. 1994. PMID: 8182049 Free article.

2

Development of C5a receptor antagonists. Differential loss of functional responses.

Konteatis ZD, Siciliano SJ, Van Riper G, Molineaux CJ, Pandya S, Fischer P, Rosen H, Mumford RA, Springer MS. Konteatis ZD, et al. Among authors: molineaux cj. J Immunol. 1994 Nov 1;153(9):4200-5. J Immunol. 1994. PMID: 7930622

3

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.

Alsina M, Trudel S, Furman RR, Rosen PJ, O'Connor OA, Comenzo RL, Wong A, Kunkel LA, Molineaux CJ, Goy A. Alsina M, et al. Among authors: molineaux cj. Clin Cancer Res. 2012 Sep 1;18(17):4830-40. doi: 10.1158/1078-0432.CCR-11-3007. Epub 2012 Jul 3. Clin Cancer Res. 2012. PMID: 22761464 Clinical Trial.

4

Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats.

Yang J, Wang Z, Fang Y, Jiang J, Zhao F, Wong H, Bennett MK, Molineaux CJ, Kirk CJ. Yang J, et al. Among authors: molineaux cj. Drug Metab Dispos. 2011 Oct;39(10):1873-82. doi: 10.1124/dmd.111.039164. Epub 2011 Jul 13. Drug Metab Dispos. 2011. PMID: 21752943

5

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.

O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, Orlowski RZ. O'Connor OA, et al. Among authors: molineaux cj. Clin Cancer Res. 2009 Nov 15;15(22):7085-91. doi: 10.1158/1078-0432.CCR-09-0822. Epub 2009 Nov 10. Clin Cancer Res. 2009. PMID: 19903785 Free PMC article. Clinical Trial.

6

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome.

Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK. Demo SD, et al. Among authors: molineaux cj. Cancer Res. 2007 Jul 1;67(13):6383-91. doi: 10.1158/0008-5472.CAN-06-4086. Cancer Res. 2007. PMID: 17616698

7

Modulatory effect of endopeptidase inhibitors on bradykinin-induced contraction of rat uterus.

Schriefer JA, Molineaux CJ. Schriefer JA, et al. Among authors: molineaux cj. J Pharmacol Exp Ther. 1993 Aug;266(2):700-6. J Pharmacol Exp Ther. 1993. PMID: 8394914

8

Regulation of beta-endorphin secretion by corticotropin-releasing factor in the intact rat testis.

Eskeland NL, Molineaux CJ, Schachter BS. Eskeland NL, et al. Among authors: molineaux cj. Endocrinology. 1992 Mar;130(3):1173-9. doi: 10.1210/endo.130.3.1537283. Endocrinology. 1992. PMID: 1537283

9

Inhibition of endopeptidase-24.15 decreases blood pressure in normotensive rats.

Genden EM, Molineaux CJ. Genden EM, et al. Among authors: molineaux cj. Hypertension. 1991 Sep;18(3):360-5. doi: 10.1161/01.hyp.18.3.360. Hypertension. 1991. PMID: 1889849

10

Endopeptidase-24.15 in rat hypothalamic/pituitary/gonadal axis.

Pierotti AR, Lasdun A, Ayala JM, Roberts JL, Molineaux CJ. Pierotti AR, et al. Among authors: molineaux cj. Mol Cell Endocrinol. 1991 Apr;76(1-3):95-103. doi: 10.1016/0303-7207(91)90264-s. Mol Cell Endocrinol. 1991. PMID: 1820981

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

30 results

Search Page